REVIEW Thalidomide is used for treating multiple myeloma in combination with dexamethasone, erythema nodosum leprosum, and alleviating symptoms of HIV, with strict controls to prevent birth defects. Thalidomide is a potent inhibitor of new blood vessel growth (angiogenesis), which is required for tumor growth.
Bejanyan N, Tiu RV, Raza A, Jankowska A, Kalaycio M, Advani A, Chan J, Saunthararajah Y, Mooney L, Maciejewski JP, Sekeres MA (2012). A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer. 118(16):3968-76. PMID 22180010.
Horton MR, Hallowell RW (2012). Revisiting thalidomide: fighting with caution against idiopathic pulmonary fibrosis. Drugs Today (Barc). 48(10):661-71. PMID 23110262.
For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.
WARNING: Attention California residents: This product can expose you to chemicals including (+/-)-Thalidomide, which is known to the State of California to cause birth defects or other reproductive harm. For more information, go to www.P65Warnings.ca.gov.